RecruitingNot Applicable

The Role of Cxcr4Hi neutrOPhils in InflueNza

France90 participantsStarted 2024-12

Plain-language summary

Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient aged 18 yo or above. * Acute respiratory distress syndrome as defined by the Berlin classification. * Invasive mechanical ventilation for less than 24 hours. * Cause of ARDS: * Influenza infection proven by polymerase chain reaction OR * Bacterial infection (tracheal aspirate with more than 105 CFU/mL and BAL with more than 104 CFU/mL. * Pancreatitis according to the 2013 Working Group IAP/APA Acute Pancreatitis Guidelines. * Peritonitis according to the 2018 SFAR guidelines. * Health insurance. * Written informed consent from legal relative or representative. Exclusion Criteria: * Neutropenia (\< 500/mm3) * Neutrophils qualitative defect. * Patient included in an interventional research assessing an immunomodulatory or antiviral drug. * Acquired ImmunoDeficiency Syndrome. * Contraindication to BAL: * Severe bronshospasm. * Out-of-control shock. * Intracranial high pressure. * Refractory hypoxemia (PaO2/FiO2 \< 60 mmHg). * Legal restriction: prisoners, pregnancy, legal protection.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Biological

Timeframe: Day 1 after inclusion

Clinical

Timeframe: Day 28 after inclusion

Trial details

NCT IDNCT06254313

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12

Contact for this trial

Renaud PREVEL, Dr

5 57 87 26 26 renaud.prevel@u-bordeaux.fr

View on ClinicalTrials.gov More Influenza trials